Cellectis S.A. (ALCLS.PA)
EUR 1.31
(-2.81%)
EUR 1.31
(-2.81%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 755 Thousand USD | -96.06% |
| 2022 | 19.17 Million USD | -74.08% |
| 2021 | 73.94 Million USD | 0.0% |
| 2020 | 73.94 Million USD | 386.83% |
| 2019 | 15.19 Million USD | 19.32% |
| 2018 | 12.73 Million USD | -49.46% |
| 2017 | 25.18 Million USD | -40.85% |
| 2016 | 42.58 Million USD | -22.63% |
| 2015 | 55.04 Million USD | 109.3% |
| 2014 | 26.29 Million USD | 15.26% |
| 2013 | 22.81 Million USD | -17.97% |
| 2012 | 27.81 Million USD | 34.19% |
| 2011 | 20.72 Million USD | -1.2% |
| 2010 | 20.98 Million USD | 21.14% |
| 2009 | 17.31 Million USD | 17.26% |
| 2008 | 14.77 Million USD | 260.13% |
| 2007 | 4.1 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.52 Million USD | 1500.0% |
| 2024 Q2 | 8.06 Million USD | 78.03% |
| 2023 Q3 | 155 Thousand USD | -12.92% |
| 2023 FY | 755 Thousand USD | -96.06% |
| 2023 Q4 | 283 Thousand USD | 82.58% |
| 2023 Q1 | 139 Thousand USD | -99.13% |
| 2023 Q2 | 178 Thousand USD | 28.06% |
| 2022 Q4 | 16.02 Million USD | 7284.33% |
| 2022 Q1 | 1.69 Million USD | -87.57% |
| 2022 FY | 19.17 Million USD | -74.08% |
| 2022 Q2 | 1.34 Million USD | -20.57% |
| 2022 Q3 | 217 Thousand USD | -83.9% |
| 2021 Q3 | 8.31 Million USD | -25.63% |
| 2021 Q2 | 11.17 Million USD | -56.35% |
| 2021 Q4 | 13.64 Million USD | 64.21% |
| 2021 FY | 73.94 Million USD | 0.0% |
| 2021 Q1 | 25.6 Million USD | 87.57% |
| 2020 FY | 73.94 Million USD | 386.83% |
| 2020 Q1 | 50.12 Million USD | 1033.37% |
| 2020 Q2 | 2.9 Million USD | -94.21% |
| 2020 Q3 | 6.18 Million USD | 113.1% |
| 2020 Q4 | 13.64 Million USD | 120.86% |
| 2019 Q2 | 1.15 Million USD | 11.2% |
| 2019 Q3 | 8.48 Million USD | 636.81% |
| 2019 FY | 15.19 Million USD | 19.32% |
| 2019 Q1 | 1.03 Million USD | 7.02% |
| 2019 Q4 | 4.42 Million USD | -47.89% |
| 2018 FY | 12.73 Million USD | -49.46% |
| 2018 Q4 | 968 Thousand USD | 6.96% |
| 2018 Q3 | 905 Thousand USD | -82.08% |
| 2018 Q2 | 5.04 Million USD | -16.41% |
| 2018 Q1 | 6.04 Million USD | 5.5% |
| 2017 Q3 | 6.12 Million USD | -9.32% |
| 2017 Q4 | 5.72 Million USD | -6.48% |
| 2017 FY | 25.18 Million USD | -40.85% |
| 2017 Q2 | 6.75 Million USD | -0.16% |
| 2017 Q1 | 6.76 Million USD | -15.39% |
| 2016 Q2 | 17.6 Million USD | 122.57% |
| 2016 Q4 | 7.99 Million USD | -29.41% |
| 2016 Q3 | 11.32 Million USD | -35.68% |
| 2016 FY | 42.58 Million USD | -22.63% |
| 2016 Q1 | 7.9 Million USD | -73.2% |
| 2015 Q2 | 8.21 Million USD | -9.95% |
| 2015 FY | 55.04 Million USD | 109.3% |
| 2015 Q1 | 9.12 Million USD | -6.77% |
| 2015 Q4 | 29.5 Million USD | 245.08% |
| 2015 Q3 | 8.55 Million USD | 4.04% |
| 2014 Q1 | 7.08 Million USD | 36.52% |
| 2014 FY | 26.29 Million USD | 15.26% |
| 2014 Q4 | 9.78 Million USD | -4.09% |
| 2014 Q3 | 10.2 Million USD | 45.1% |
| 2014 Q2 | 7.03 Million USD | -0.64% |
| 2013 Q3 | 5.09 Million USD | 51.04% |
| 2013 Q4 | 5.18 Million USD | 1.75% |
| 2013 FY | 22.81 Million USD | -17.97% |
| 2013 Q1 | 3.32 Million USD | 18.94% |
| 2013 Q2 | 3.37 Million USD | 1.46% |
| 2012 Q4 | 2.79 Million USD | -67.85% |
| 2012 FY | 27.81 Million USD | 34.19% |
| 2012 Q3 | 8.69 Million USD | 0.0% |
| 2011 FY | 20.72 Million USD | -1.2% |
| 2010 FY | 20.98 Million USD | 21.14% |
| 2009 FY | 17.31 Million USD | 17.26% |
| 2008 FY | 14.77 Million USD | 260.13% |
| 2007 FY | 4.1 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 83.728% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 83.662% |
| Adocia SA | 2.15 Million EUR | 64.884% |
| Aelis Farma SA | 9.05 Million EUR | 91.661% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 76.039% |
| genOway Société anonyme | 20.04 Million EUR | 96.234% |
| IntegraGen SA | 12.53 Million EUR | 93.978% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -151.638% |
| Neovacs S.A. | 533.41 Thousand EUR | -41.542% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 55.1% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -3713.902% |
| Sensorion SA | 4.74 Million EUR | 84.082% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -154.783% |
| TME Pharma N.V. | 17 Thousand EUR | -4341.176% |
| Valbiotis SA | 4.73 Million EUR | 84.048% |
| TheraVet SA | 1.07 Million EUR | 29.966% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 58.056% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Genfit S.A. | 28.56 Million EUR | 97.357% |
| GeNeuro SA | - EUR | -Infinity% |
| Innate Pharma S.A. | 51.9 Million EUR | 98.545% |
| Inventiva S.A. | 17.47 Million EUR | 95.68% |
| MaaT Pharma SA | 2.22 Million EUR | 66.113% |
| MedinCell S.A. | 9.16 Million EUR | 91.758% |
| Nanobiotix S.A. | 30.05 Million EUR | 97.488% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 66.098% |
| Poxel S.A. | 1.98 Million EUR | 61.888% |
| GenSight Biologics S.A. | 1.26 Million EUR | 40.41% |
| Transgene SA | 1.18 Million EUR | 36.233% |
| Valneva SE | 153.71 Million EUR | 99.509% |